Annual report pursuant to Section 13 and 15(d)

Schedule of Accrued Expenses (Details) (Parenthetical)

v3.24.1
Schedule of Accrued Expenses (Details) (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Apr. 08, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Deferred revenue [1]   $ 88
Cystic Fibrosis Foundation Therapeutics Development Award [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Deferred revenue     88
BioNTech Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue recognized   $ 2,750 688
BioNTech Agreement [Member] | License and Service [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue recognized 688    
BioNTech Agreement [Member] | Health Care, Patient Service [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue recognized $ 375    
Genentech Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue recognized     $ 33
[1] At December 31, 2022, the balance of $88 was related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements).